2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°Á : 2024-05-18
±³À°ÀÏÀÚ : 2024-05-18
±³À°Àå¼Ò : ¼¿ï´ëÇб³ ¾Ï¿¬±¸¼Ò ÀÌ°ÇÈñȦ
±³À°ÁÖÁ¦ : 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : kspho@kams.or.kr
±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú
Âü¼®¿¹»óÀÎ : 70¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50,000¿ø, Àü°øÀÇ/°£È£»ç 30,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 10:30~11:00 2023 ASH review, ALL(acute lymphoblastic leukemia) /lymphoma Á¶¼öÁ¤(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 11:00~11:30 2023 ASH review, AML/MDS(acute myeloid leukemia/ myelodysplastic syndrome) ±èº¸°æ(¼¿ïÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 11:30~12:00 2023 SIOP review, Recent update of pediatic oncology' ÀÌÀº»ó(°í·ÁÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 13:00~13:40 Hemangioma Á¤Çý¸²(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 13:50~14:20 General management of patients with childhood cancers ¼Áø°æ(±¹¸³¾Ï¼¾ÅÍ )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 14:20~14:50 Chemotherapy-induced adverse event management ¾çÀ¯Áø(ºÎ»êÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 14:50~15:20 Management of immunotherapy, target agents, and cell therapy associated adverse reaction Á¶Èñ¿ø(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 15:30~16:00 Acute lymphoblastic leukemia À¯Àç¿ø(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 16:00~16:30 Acute myeloid leukemia °¼ºÇÑ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 16:30~17:00 Lymphoma ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë )